INDV — Indivior Pharmaceuticals Inc stock price, charts and financials
QT69Indivior Pharmaceuticals IncIndivior Pharmaceuticals Inc (NASDAQ: INDV) is a Healthcare company in the Drug Manufacturers - Specialty & Generic industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
34.88
-0.81-2.27%
Filing
Down 2.3% — Filed an 8-K material-event report (2026-09-17) — details in the filing.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | 12.50 | EPS (ttm) | 2.79 | Insider Own | 1.86% | Shs Outstand | 124.77M | Perf Week | 1.13% |
| Market Cap | 4.35B | Forward P/E | 7.55 | EPS next Y | 4.62 | Insider Trans | -3.02% | Shs Float | 112.13M | Perf Month | -10.66% |
| Enterprise Value | 4.64B | PEG | 1.95 | EPS next Q | 1.06 | Inst Own | - | Short Float | 10.08% | Perf Quarter | -8.93% |
| Income | 355.00M | P/S | 3.27 | EPS this Y | 51.31% | Inst Trans | - | Short Ratio | 5.55 | Perf Half Y | 14.36% |
| Sales | 1.33B | P/B | - | EPS next Y | 9.44% | ROA | 28.79% | Short Interest | 11.30M | Perf YTD | -2.79% |
| Book/sh | -1.67 | P/C | 19.60 | EPS next 5Y | 6.40% | ROE | -216.13% | 52W High | 42.81 -18.52% | Perf Year | 51.85% |
| Cash/sh | 1.78 | P/FCF | - | EPS past 3/5Y | - | ROIC | 125.11% | 52W Low | 22.22 56.98% | Perf 3Y | 56.13% |
| Dividend Est. | - | EV/EBITDA | 10.74 | Sales past 3/5Y | 11.20% 13.88% | Gross Margin | 83.86% | Volatility | 2.81% 2.76% | Perf 5Y | 150.04% |
| Dividend TTM | - | EV/Sales | 3.48 | EPS Y/Y TTM | 18500.00% | Oper. Margin | 38.89% | ATR (14) | 1.06 | Perf 10Y | 64.14% |
| Dividend Ex-Date | Oct 30, 2026 | Quick Ratio | 0.66 | Sales Y/Y TTM | 12.12% | Profit Margin | 26.65% | RSI (14) | 41.95 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.84 | EPS Q/Q | 125.49% | SMA20 | -0.49% | Beta | 1.17 | Target Price | 48.00 |
| Payout | 0.00% | Debt/Eq | 5.27 | Sales Q/Q | 13.58% | SMA50 | -7.47% | Rel Volume | 2.12 | Prev Close | 35.69 |
| Employees | 833 | LT Debt/Eq | -3.18 | Earnings | Oct 29 | SMA200 | -2.28% | Avg Volume | 2.12M | Price | 34.88 |
| IPO Date | Dec 29, 2014 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 32.30% 12.01% | Net Debt/EBITDA | 0.66 | Volume | 4,507,613 | Change | -2.27% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-05-26 | Reiterated | Barclays | Overweight | $46 → $43 |
| Aug-04-26 | Reiterated | Craig-Hallum | Buy | $50 → $53 |
| Jun-18-26 | Initiated | Barclays | Overweight | $46 |
| Jan-20-26 | Reiterated | Northland Securities | $40 → $50 | |
| Jan-12-26 | Reiterated | HC Wainwright & Co. | Buy | $35 → $48 |
| Dec-03-25 | Reiterated | Morgan Stanley | $28 → $36 | |
| Oct-31-25 | Reiterated | Craig-Hallum | Buy | $34 → $41 |
| Oct-31-25 | Reiterated | Northland Securities | $30 → $40 | |
| Oct-30-25 | Reiterated | HC Wainwright & Co. | Buy | $35 |
| Aug-27-25 | Reiterated | Craig-Hallum | Buy | $20 → $34 |
Latest News· Times ET
Sep-14-26
Sep-11-26
Sep-11-2611:39PM
Sep-02-26
Sep-02-2611:30AM
Aug-29-26
Aug-29-2604:00AM
Aug-21-26
Aug-17-26
Aug-07-26
Aug-07-2608:00AM
Aug-05-26
Aug-05-2612:05PM
Aug-04-26
Aug-03-26
Aug-03-2611:44AM
11:15AM
08:14AM
06:44AM
06:44AM
Company
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,332 | 1,239 | 1,188 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 215 | 246 | 231 | — | — | — | — | — | — | |
| Gross Profit | 1,117 | 993 | 957 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 534 | 634 | 618 | — | — | — | — | — | — | |
| Research and Development | 65 | 97 | 107 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | -3 | 200 | — | — | — | — | — | — | |
| Operating Income | 518 | 265 | 32 | — | — | — | — | — | — | |
| Interest Expense | 27 | 45 | 41 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -98 | 19 | 23 | — | — | — | — | — | — | |
| Net Income Before Taxes | 393 | 239 | 14 | — | — | — | — | — | — | |
| Income Taxes | 38 | 29 | 11 | — | — | — | — | — | — | |
| Consolidated Net Income | 355 | 210 | 2 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 355 | 210 | 3 | — | — | — | — | — | — | |
| Net Income | 355 | 210 | 2 | — | — | — | — | — | — | |
| EPS (Recurring) | 2.84 | 1.68 | 0.02 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 2.84 | 1.68 | 0.02 | — | — | — | — | — | — | |
| EPS (Diluted) | 2.79 | 1.64 | 0.02 | — | — | — | — | — | — | |
| EBITDA | 432 | 304 | 84 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 12.50 | 21.88 | 828.67 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.27 | 3.62 | 1.38 | — | — | — | — | — | — | |
| Gross Margin | 83.86 | 80.15 | 80.56 | — | — | — | — | — | — | |
| Operating Margin | 38.89 | 21.39 | 2.69 | — | — | — | — | — | — | |
| Net Margin | 26.65 | 16.95 | 0.17 | — | — | — | — | — | — | |
| Shares Outstanding | 125 | 125 | 132 | — | — | — | — | — | — | |
| Market Capitalization | 4,360 | 4,485 | 1,641 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Anderson Woodrow D | Chief Accounting Officer | Aug 27 '26 | Buy | 35.69 | 1,500 | 53,535 | 27,638 | Aug 27 |
| Anderson Woodrow D | Chief Accounting Officer | Aug 05 '26 | Buy | 36.28 | 1,500 | 54,420 | 26,138 | Aug 05 |
| Heidbreder Christian | Chief Scientific Officer | Jul 10 '26 | Sale | 41.14 | 18,586 | 764,628 | 209,337 | Jul 13 |
| Ciaffoni Joseph | Chief Executive Officer | Jun 22 '26 | Option Exercise | 0.00 | 1,266,903 | 0 | 1,402,879 | Jun 23 |
| Heidbreder Christian | Chief Scientific Officer | Jun 11 '26 | Sale | 38.06 | 18,586 | 707,383 | 227,923 | Jun 12 |
| Preblick Ryan | Chief Financial Officer | Jun 08 '26 | Sale | 37.70 | 36,000 | 1,357,200 | 284,751 | Jun 10 |
| Preblick Ryan | Chief Financial Officer | Mar 14 '26 | Option Exercise | 0.00 | 6,302 | 0 | 323,594 | Mar 17 |
| Ryan Barbara | Director | Mar 13 '26 | Buy | 31.09 | 8 | 249 | 5,724 | Mar 13 |
| Ryan Barbara | Director | Mar 09 '26 | Buy | 32.56 | 31 | 1,009 | 5,716 | Mar 11 |
| Kingsley Stuart A | Director | Mar 06 '26 | Buy | 31.86 | 940 | 29,953 | 5,582 | Mar 11 |
| Anderson Woodrow D | Chief Accounting Officer | Mar 03 '26 | Option Exercise | 0.00 | 48,285 | 0 | 29,657 | Mar 05 |
| Preblick Ryan | Chief Financial Officer | Mar 03 '26 | Option Exercise | 0.00 | 200,459 | 0 | 317,292 | Mar 05 |
| Burris Jeffrey W | Chief Legal Officer | Mar 03 '26 | Option Exercise | 0.00 | 184,193 | 0 | 107,550 | Mar 05 |
| Heidbreder Christian | Chief Scientific Officer | Mar 03 '26 | Option Exercise | 0.00 | 234,109 | 0 | 292,306 | Mar 05 |
| Ryan Barbara | Director | Jan 05 '26 | Buy | 35.39 | 775 | 27,429 | 1,963 | Jan 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.